AVITA Medical, Inc. RCEL
AVITA Medical, Inc. (Nasdaq: RCEL) is a dermatology drug developer. Its lead program, RECELL, is marketed for thermal burn wounds and full-thickness skin defects. Its next catalyst on record is RECELL (CPT code reimbursement): CMS final rules for 2027 Medicare Physician Fee Schedule expected (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RECELL (CPT code reimbursement) — CMS final rules for 2027 Medicare Physician Fee Schedule expected (2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RECELL Autologous Cell Harvesting Device (RECELL EOU) | thermal burn wounds and full-thickness skin defects | cell therapy | Approved |
| RECELL GO Autologous Cell Harvesting Device | thermal burn wounds and full-thickness skin defects | cell therapy | Approved |
| RECELL GO mini Autologous Cell Harvesting Device | thermal burn wounds and full-thickness skin defects (smaller wounds up to 480 cm2) | cell therapy | Approved |
| Cohealyx | dermal matrix for wound bed preparation | biologic-other | Approved |
| PermeaDerm | biosynthetic wound matrix | biologic-other | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved dermatology companies
- Journey Medical Corp DERM
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.